Ifinatamab deruxtecan, IRINOTECAN HYDROCHLORIDE, DOCETAXEL, PACLITAXEL
DS7300-202
Phase 3 small_molecule active
Quick answer
Ifinatamab deruxtecan, IRINOTECAN HYDROCHLORIDE, DOCETAXEL, PACLITAXEL for Esophageal Squamous Cell Carcinoma (ESCC) is a Phase 3 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active